BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...for the anti-ILT4 mAb.Checkpoint ligands MICA, MICB, NCR1...
...cell therapies, and the only program against NCR1...
BioCentury | Mar 15, 2021
Product Development

As investors welcome early efficacy signal, Rubius sees platform validation in results

Rubius believes an early readout from its lead program in solid tumors represents a validating event for its RED platform, but after seeing a 13% overall response rate in a clinical study, the company is...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Apr 8, 2020
Deals

COVID-19 roundup: U.S. to freeze WHO funding as Wellcome calls on CEOs to support $8B fund; plus Ridgeback-Emory, Karyopharm, IQVia and more

...in 2021. Cytovia will be responsible for one arm of the therapy, which will target NCR1...
...of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Targets NCR1 (NKP46; CD335) - Natural cytotoxicity triggering receptor 1...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

...binding CD16 and a bispecific Fv domain targeting tumor antigens and the NK cell-activating receptor NCR1...
...for biosimilar versions of rituximab. TARGET/MARKER/PATHWAY: Fc γ receptor III (CD16; FCGR3); natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335...
...Aix-Marseille University, Marseille, France email: vivier@ciml.univ-mrs.fr Sandi Wong Aix-Marseille University Innate Pharma S.A. Sanofi AstraZeneca plc Fc gamma receptor III (CD16) (FCGR3) Natural cytotoxicity triggering receptor 1 (NCR1) (NKP46) (CD335) Lymphoma...
BioCentury | Jun 20, 2018
Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma Cell culture and mouse studies suggest adoptive transfer of IL-15-cultured T cells could help treat B7-H6 tumor cell ligand-positive cancers. CD8 + T cells derived from human donor blood and cultured for...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...CT101-IL2 Fusion protein NKG2D Preclin Innate Pharma S.A. (Euronext:IPH) IPH61 Bispecific antibody Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335...
BioCentury | Mar 13, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Candida; fungal infection Cell culture studies identified a glucan-based NKp30 activator that could help treat Cryptococcus neoformans and Candida albicans infections. In vitro , a C. neoformans and C. albicans cell wall glucan bound NKp30...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest activating or overexpressing NCR2 could help treat melanoma. In a human melanoma cell line, supernatant from NK cells activated by the NCR2 ligand PDGFDD decreased growth compared...
Items per page:
1 - 10 of 43